Trials / Unknown
UnknownNCT04539600
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
Induction Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is a single center phase II trial. The purpose is to investigate both the efficacy and safety of chemotherapy combined with anti-PD-1 antibody Followed by chemoradiotherapy in locoregionally advanced hypopharyngeal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer. |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2022-07-31
- Completion
- 2022-12-12
- First posted
- 2020-09-07
- Last updated
- 2021-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04539600. Inclusion in this directory is not an endorsement.